YS

- · NASDAQ

Sector -
Industry -
Website ysbiopharm.com
Employees(FY) 754
ISIN -

Performance

YTD

Profile

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Advanced Technical Analysis

Recent News & Updates

2024-05-23 19:30
YS Biopharma Announces Name Change to LakeShore Biopharma(Prnewswire)
2024-05-21 04:15
YS Biopharma Announces Results of Extraordinary General Meeting(Prnewswire)
2024-05-07 04:20
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer(Prnewswire)
2024-04-28 20:00
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule(Prnewswire)
2024-04-21 21:10
YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript(Insidermonkey)
2024-04-18 23:52
YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024(Investorplace)
2024-04-18 19:00
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024(Prnewswire)
2024-04-17 20:00
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine(Prnewswire)
2024-04-15 20:00
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024(Prnewswire)
2024-04-08 22:06
YS Biopharma's rabies vaccine bests approved competitor in interim phase 3 readout(Fiercebiotech)
2024-04-08 20:00
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine(Prnewswire)
2024-04-02 20:00
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility(Prnewswire)
2024-03-04 19:00
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries(Prnewswire)
2024-02-22 04:00
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024(Prnewswire)
2024-02-17 15:30
/C O R R E C T I O N -- YS Biopharma Co., Ltd./(Yahoo Finance)
2024-02-16 07:20
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting(Prnewswire)
2024-02-16 04:36
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.(Prnewswire)
2024-02-13 19:00
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance(Prnewswire)
2024-02-13 18:50
YS Biopharma Announces Appointment of New Directors(Prnewswire)
2024-02-11 19:50
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.(Prnewswire)
2024-02-08 17:30
YS Biopharma Announces US$40 Million Private Placement Financing(Prnewswire)
2024-02-08 05:10
Shareholders of YS Biopharma Announce an Extraordinary General Meeting(Prnewswire)
2024-01-24 03:00
Diamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS)(Globenewswire)
2024-01-22 09:51
YS Stock Earnings: YS Biopharma Co Misses EPS, Misses Revenue for Q2 2024(Investorplace)
2024-01-22 04:00
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024(Prnewswire)
2024-01-07 19:00
YS Biopharma Announces Changes to its Board Committees(Prnewswire)
2023-12-20 03:30
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting(Prnewswire)
2023-12-20 03:15
/DISREGARD RELEASE: YS Biopharma/(Redinews)
2023-12-19 19:56
YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023(Prnewswire)
2023-11-13 19:30
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target(Prnewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.